Additionally, Acat1 KD may indirectly enhance antitumor immune efficacy by decreasing the proportion of monocyte-derived tumor-associated macrophages (TAMs), tumor-associated DCs (TADCs), and myeloid-derived suppressor cells (MDSCs) in the TME, all of which primarily mediate an immunosuppressive microenvironment (53). This evidence concerns the gene ACAT1 and neoplasm.